![]() |
市場調查報告書
商品編碼
1635909
2025-2033 年按類型(活性藥物成分、添加劑、成品)、服務、最終用戶和地區分類的藥物分析測試外包市場Pharmaceutical Analytical Testing Outsourcing Market by Type (Active Pharmaceutical Ingredients, Additives, Finished Products), Service, End User, and Region 2025-2033 |
2024年全球藥物分析測試IMARC Group市場規模達90億美元。該市場的推動因素包括人們對脂質體、奈米粒子和微球等新型藥物傳遞系統的日益關注,癌症、糖尿病和心血管疾病等慢性疾病盛行率的增加,以及對藥物開發的日益重視。
藥品分析測試外包是製藥業使用的測試活動,透過將部分工作外包給第三方來最大限度地降低內部生產成本。作為合約研究組織的延伸,藥物分析測試外包服務已經開始取代很大一部分內部分析開發和測試。作為藥物和療法開發過程的一部分,藥物測試從一開始到產品商業化都發揮著至關重要的作用。它需要確定化學品的結構、純化物質混合物以及合成和表徵活性藥物成分 (API)。該計劃通常涉及配方開發和早期製造,以加速複合活動。
該市場的主要推動力是製藥公司、合約研究組織和生物技術公司擴大採用外包實踐。這可以歸因於各個監管機構對藥物開發端到端過程的分析資訊的需求不斷增加。此外,不斷的技術進步以及對縮短產品生命週期的關注導致新產品的快速開發,這為市場提供了動力。對產品安全和品質的需求不斷成長、體內和體外測試法規的變化以及對客製化護理的日益重視也對市場產生了積極影響。組合產品、生物相似藥和其他創新藥物的開發導致了特定類型測試和特殊產品製造的引入,進一步推動了市場的發展。對該市場做出貢獻的其他一些因素包括製藥業的眾多創新、外包的定價優勢、為開發永續藥物而進行的廣泛研究和開發(R&D)、多個國家政府的有利舉措以及越來越多的臨床試驗註冊。
The global pharmaceutical analytical testing outsourcing market size reached USD 9.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.49% during 2025-2033. The market is driven by the growing focus on new drug delivery systems, such as liposomes, nanoparticles, and microspheres, increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disease, and rising emphasis on drug development.
Pharmaceutical analytical testing outsourcing is a testing activity used in the pharmaceutical industry to minimize in-house production costs by outsourcing parts of the work to a third party. As an extension of contract research organizations, pharmaceutical analytical testing outsourcing services have begun replacing a significant portion of in-house analytical development and testing. As part of the development process for drugs and therapies, pharmaceutical testing plays a vital role from the beginning through the commercialization of the product. It entails determining the structures of chemicals, purifying a mixture of substances, and synthesizing and characterizing active medicinal ingredients (APIs). Formulation development and early-phase manufacturing are usually involved in this initiative to speed up compound activities.
The market is majorly driven by the increasing adoption of outsourcing practices in pharmaceutical companies, contract research organizations, and biotech companies. This can be attributed to the escalating demand for analytical information on the end-to-end process of drug development by various regulatory agencies. Additionally, continual technological advancements with an enhanced focus on shortening the product lifecycle have resulted in the rapid development of new products, which is providing an impetus to the market. The rising need for product safety and quality, changing regulations for in vivo and in vitro tests, and an augmented emphasis on customized care is also impacting the market positively. The development of combination products, biosimilar, and other innovative medicines leading to the introduction of specific types of tests and specialty product manufacturing are further fueling the market. Some of the other factors contributing to the market include numerous innovations in the pharmaceutical industry, the pricing benefits of outsourcing, extensive research and development (R&D) conducted to develop sustainable drugs, favorable initiatives by the governments of several countries, and the growing number of clinical trial registrations.
Active Pharmaceutical Ingredients (API)
Additives
Finished Products
Bioanalytical Testing
Clinical
Non-Clinical
Method Development and Validation
Extractable and Leachable
Impurity Method
Technical Consulting
Others
Stability Testing
Drug Substance
Stability Indicating Method Validation
Accelerated Stability Testing
Photostability Testing
Others
Others
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Research Organizations
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Bio-Pharma Services (Ajinomoto Co. Inc.), Alcami Corporation Inc., Boston Analytical Inc., Catalent Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Intertek Group plc, Laboratory Corporation of America Holdings, Pace Analytical Services LLC, SGS S.A., Thermo Fisher Scientific Inc., West Pharmaceutical Services Inc. and WuXi AppTec Inc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
The global pharmaceutical analytical testing outsourcing market size reached USD 9.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.49% during 2025-2033. The market is driven by the growing focus on new drug delivery systems, such as liposomes, nanoparticles, and microspheres, increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disease, and rising emphasis on drug development.
Pharmaceutical analytical testing outsourcing is a testing activity used in the pharmaceutical industry to minimize in-house production costs by outsourcing parts of the work to a third party. As an extension of contract research organizations, pharmaceutical analytical testing outsourcing services have begun replacing a significant portion of in-house analytical development and testing. As part of the development process for drugs and therapies, pharmaceutical testing plays a vital role from the beginning through the commercialization of the product. It entails determining the structures of chemicals, purifying a mixture of substances, and synthesizing and characterizing active medicinal ingredients (APIs). Formulation development and early-phase manufacturing are usually involved in this initiative to speed up compound activities.
The market is majorly driven by the increasing adoption of outsourcing practices in pharmaceutical companies, contract research organizations, and biotech companies. This can be attributed to the escalating demand for analytical information on the end-to-end process of drug development by various regulatory agencies. Additionally, continual technological advancements with an enhanced focus on shortening the product lifecycle have resulted in the rapid development of new products, which is providing an impetus to the market. The rising need for product safety and quality, changing regulations for in vivo and in vitro tests, and an augmented emphasis on customized care is also impacting the market positively. The development of combination products, biosimilar, and other innovative medicines leading to the introduction of specific types of tests and specialty product manufacturing are further fueling the market. Some of the other factors contributing to the market include numerous innovations in the pharmaceutical industry, the pricing benefits of outsourcing, extensive research and development (R&D) conducted to develop sustainable drugs, favorable initiatives by the governments of several countries, and the growing number of clinical trial registrations.
Active Pharmaceutical Ingredients (API)
Additives
Finished Products
Bioanalytical Testing
Clinical
Non-Clinical
Method Development and Validation
Extractable and Leachable
Impurity Method
Technical Consulting
Others
Stability Testing
Drug Substance
Stability Indicating Method Validation
Accelerated Stability Testing
Photostability Testing
Others
Others
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Research Organizations
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Bio-Pharma Services (Ajinomoto Co. Inc.), Alcami Corporation Inc., Boston Analytical Inc., Catalent Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Intertek Group plc, Laboratory Corporation of America Holdings, Pace Analytical Services LLC, SGS S.A., Thermo Fisher Scientific Inc., West Pharmaceutical Services Inc. and WuXi AppTec Inc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.